SNIPR CVM
Alternative Names: SNIPR-CVMLatest Information Update: 02 Feb 2024
At a glance
- Originator SNIPR Biome
- Class Cardiovascular therapies; Gene therapies
- Mechanism of Action Gene expression modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cardiovascular disorders; Metabolic disorders
Most Recent Events
- 16 Jan 2024 SNIPR CVM is available for licensing as of 16 Jan 2024. https://sniprbiome.com/partnering (SNIPR Biome pipeline, January 2024)
- 16 Jan 2024 Preclinical trials in Cardiovascular disorders in Denmark (unspecified route) prior to January 2024 (SNIPR Biome pipeline, January 2024)
- 16 Jan 2024 Preclinical trials in Metabolic disorders in Denmark (unspecified route) prior to January 2024 (SNIPR Biome pipeline, January 2024)